The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
about
Cell-free circulating tumor DNA in cancerLiquid biopsy in early stage lung cancerKRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsDNA studies using atomic force microscopy: capabilities for measurement of short DNA fragmentsPrognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Liquid biopsy: monitoring cancer-genetics in the blood.Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer.A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.Changing paradigm of cancer therapy: precision medicine by next-generation sequencing.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.Cell-free DNA as a novel marker in cancer therapy.The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?Liquid biopsies come of age: towards implementation of circulating tumour DNA.Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysisThe prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Circulating tumor DNA (ctDNA) in the era of personalized cancer therapyCirculating cell-free DNA: a potential biomarker in lung cancer
P2860
Q26750899-2E2CC5D6-146B-4B5E-894E-E924AD60125CQ28065994-33210347-BAC9-4C99-A5B7-2F32313D548BQ28077570-0A19FCD3-7820-419F-9B61-1C7BF48E562AQ28080979-78E5B9A4-799F-4CAE-8781-D2B410CA3B47Q33779727-95680949-6A80-4B46-B891-76969AF2D4CCQ33829668-70E4C22F-7204-4E17-B716-BC734743CEF2Q34356149-C7962C5A-952A-45F9-AF1B-A60EA27BB138Q34577740-203EE734-DBFF-4A14-BF4F-89BC685CC1D3Q35828697-28215614-C3EF-4A84-9A84-C1F98CDD0ACCQ36378903-824F9775-548B-45BA-9ED9-723C1EDC2A9CQ36384490-179C910E-9403-4DA5-BC8B-E30FD1E8DC2BQ36849642-0AA05D49-DE49-473E-A645-B7EDC06E77BDQ36946809-26869A1D-55D4-450C-9A4F-21A9A0B4DD32Q37242412-12C3F9C6-B264-4B91-B74C-8B32094E7D8CQ37536958-C3F7DBF4-9CBE-418A-B9F3-75707EC3AAC1Q37690677-41CEA0C5-2C0E-49FF-8EE9-FBA822332AD5Q38152782-EBF7FBD1-A780-44F7-8713-549DBDB77059Q38261856-F8CF61B5-27DB-4B6E-888B-D5C5A1428002Q38263419-86D5C585-6025-4519-A70F-34F981C88F1AQ38376337-8615B261-0EF2-44CB-8EDF-1F9C589545CEQ38376723-0BBF514D-6201-490C-B5C4-7ACE4B188DF4Q38547170-C8CF5E9E-444B-4694-BC54-5C58A6FB87D2Q39097813-49DFD770-D0A7-400D-90EE-4CC359DD4089Q39142265-B133EE9A-C81C-4110-918E-B50288320BE5Q39149201-CA5CEFB5-0DF0-4938-9A58-8403919D1DC2Q40429924-4D39D59B-3D68-4A4F-94B1-E9C45E751CD2Q41162179-9AEC37B7-EE04-4C15-A2AD-25536C941B32Q41347759-CD8B74FA-511D-44D4-8F77-DDB1B96D6EA2Q47563363-F6AD370B-C44E-411E-8206-036AA042B783Q48527971-DD404850-F2E9-4632-B784-4644853A93DBQ49740946-989953CF-65B6-4D32-9127-CC6DD093ECB1Q51437092-64345E0E-6F07-4BF0-B546-6B180E1D31AAQ53165144-7C3E655D-A760-4BD9-B16A-4E4648275678Q57147396-435EE845-919C-4825-8262-779DCE7CBB2DQ57306273-72BC7419-970B-4A8B-BF5F-B014E2C294D1
P2860
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@ast
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@en
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@nl
type
label
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@ast
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@en
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@nl
prefLabel
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@ast
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@en
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
@nl
P2093
P1433
P1476
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer
@en
P2093
Anneli Dowler Nygaard
Karen-Lise Garm Spindler
Niels Pallisgaard
P304
P356
10.1016/J.LUNGCAN.2012.11.016
P577
2012-12-11T00:00:00Z